BiotechTube
Purdue Pharma

Purdue Pharma

Stamford, United States
purduepharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $2.8B

Overview

Purdue Pharma is a U.S.-based pharmaceutical company in the final stages of a court-approved Chapter 11 bankruptcy reorganization, set to re-emerge as Knoa Pharma. Historically known for its role in the opioid epidemic, the restructured company aims to pivot towards a future centered on a pipeline of novel therapeutics while continuing to meet obligations from its legacy business. Its current operations include developing a clinical-stage oncology asset and maintaining a stated commitment to funding opioid crisis abatement programs as part of its bankruptcy settlement.

OncologyPain Management

Funding History

1
Total raised:$2.8B
Debt$2.8B

FDA Approved Drugs

1
OXYCONTINNDAApr 5, 2010

Opportunities

The primary opportunity is the development of tinostamustine as a first-in-class treatment for glioblastoma, a high-need oncology market.
Furthermore, the restructured company (Knoa Pharma) has a unique opportunity to establish a novel public trust model, where commercial success in drug development directly funds billions of dollars for opioid crisis abatement and victim compensation.

Risk Factors

Extreme reputational risk from the opioid litigation legacy may hinder partnerships and commercial efforts.
The clinical and commercial success of the post-bankruptcy pipeline, starting with tinostamustine, is highly uncertain.
The company also faces execution risk in transitioning to an unprecedented public benefit trust governance and operational model.

Competitive Landscape

In glioblastoma, tinostamustine will compete against standard chemotherapies, emerging immunotherapies, and other novel agents in development. As a restructured entity, its broader competitive landscape is unique; its 'competitors' are not just other pharma firms but also the challenge of generating sufficient profit to meet its massive settlement funding obligations, which will require successful drug launches in competitive therapeutic markets.

More companies in Small Molecule Drugs →More companies in United States →